Detection of SARS-CoV-2 by rapid antigen tests on saliva in hospitalized patients with COVID-19

Yang De Marinis a,b,c, Anne-Katrine Pesola d, Anna Söderlund Strand d, Astrid Norman e, Gustav Pernow e, Markus Aldén e, Runtao Yang f and Magnus Rasmussen e

aDepartment of Clinical Sciences Malmö, Lund University, Malmö, Sweden; School of Control Science and Engineering, Shandong University, Jinan, China; bDepartment of Endocrinology and Metabolism, Division of Life Sciences of Medicine, University of Science and Technology of China, Hefei, China; cClinical Microbiology, Skåne University Hospital, Lund, Sweden; dDivision of Infection Medicine, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; eSchool of Mechanical, Electrical and Information Engineering, Shandong University, Weihai, China

ABSTRACT

Introduction

Coronavirus disease (COVID-19) caused by SARS-CoV-2 has led to over 241 million reported infection cases and 4.9 million deaths worldwide [1]. COVID-19 has had a tremendous impact on public health, economics, and social activities; and affects many aspects of daily life. One of the most important prevention and control measurements is rigorous testing and tracking of SARS-CoV-2 in the general population.

Different diagnostic methods have been developed by targeting the genetic material or major structural proteins of SARS-CoV-2. RT-PCR detects the presence of viral RNA in a specimen, whereas antigen test detects the presence of viral proteins. Both methods are applied to confirm ongoing infection and are often performed on nasopharyngeal (NPH) swab samples [2–4].

The rapid antigen tests for the detection of SARS-CoV-2 have been applied in various clinical settings and population screenings. This method is based on a rapid chromatographic immunoassay and designed for the qualitative detection of specific antigens of SARS-CoV-2. The rapid antigen test is not restricted to centralized testing and can be used as a fast point-of-care diagnostic method. Nevertheless, most commercially available antigen tests are designed to be performed on NPH swab samples [4,5]. This procedure causes discomfort for the patients and requires health-care professionals, and therefore limits its application on self-testing in the general population [6].

Previous studies have shown that SARS-CoV-2 can be detected in saliva of asymptomatic carriers, outpatients, as well as hospitalized patients [7–10]. A recent investigation compared viral load by reverse transcriptase digital polymerase chain reaction (RT-dPCR) in saliva, sputum, NPH swab, oropharyngeal swab, anal swab, and feces; and showed that NPH had the highest positive rate (93%) among the six types of specimens, followed by saliva detection (86%) [9].

In this study, we explored the possibility to detect SARS-CoV-2 in saliva specimens as an alternative to NPH samples. We also investigated the application of
rapid antigen tests on saliva specimens with respect to disease duration and RT-qPCR Ct values.

Methods

Study cohort participants
A total of 44 hospitalized patients with COVID-19 diagnosed at Skåne University Hospital (Lund, Sweden) provided written informed consent to participate in this study. COVID-19 had been confirmed with a positive RT-PCR test on NPH swab specimen at hospital admission. After consent to participate, approximately 1 ml of saliva in a sterile plastic tube and a new NPH-swab in 1 ml of sterile 0.9% sodium chloride solution from the patients were obtained and stored at -80°C until analysis in-batch. Disease duration in days and severity according to need for supportive care were identified through the medical record system.

Detection of SARS-CoV-2 by RT-qPCR
Among 44 NPH samples collected, detection of SARS-CoV-2 in saliva in 41 of the NPH swab specimens was performed by RT-qPCR, using the MagNA pure 96 automated platform (Roche Life Science). This was followed by PCR-analysis of the envelope gene using a 7500 Fast Real-time PCR system (Applied Biosystems) as previously described [11] with modifications. The PCR cycling program was 48°C for 10 min, 95°C for 10 min and 45 cycles of 95°C for 15 s and 55°C for 45 s. PCR-analyses were performed using the Path-ID Multiplex one-step kit (Thermo-Fisher Scientific) and expressed as Cycle of threshold (Ct). One NPH swab specimen was analyzed using a non-commercial extraction technique followed by PCR analysis targeting the envelope gene using a QuantStudio 7 instrument (Applied Biosystems). Two NPH swab specimens were analyzed using the BioFire FilmArray Respiratory 2.1 Panel (BioMerieux).

Detection of SARS-CoV-2 by rapid antigen tests
Saliva samples from the cohort participants were thawed to room temperature prior to testing. Four SARS-CoV-2 rapid antigen tests were used in this study: Flowflex (Flowflex SARS-CoV-2 Rapid Antigen Test, ZetaGene-Hughes Healthcare, Sweden/UK), Panbio (Panbio COVID-19 Ag Rapid Test, Abbott, UK), Joinstar (Joinstar COVID-19 Antigen Rapid Test (Colloidal gold), China), PCL (PCL COVID-19 Ag Antigen Gold Saliva Lateral Flow Test, Korea). Saliva samples were collected by the swabs provided in respective kits, except for the PCL where saliva and buffer were mixed 1:1 by pipetting. Testing was performed following instructions from respective manufacturer.

Ethics
The study was performed in accordance with the Declaration of Helsinki. Patients in the study cohort included gave informed consent to sample collection and study participation. The study was approved by the national ethics review board (2020–01747, and 2020–05361 for amendment).

Statistical analysis
Wilcoxon signed-rank test was performed to compare RT-PCR values from NPH and saliva of the patients. Pearson’s correlation coefficient analysis was performed to measure the degree of correlation between each two random variables among saliva-PCR-Ct values, NPH-PCR-Ct values, and symptom duration.

Data and resource availability
Data presented in this manuscript are available upon reasonable request to the corresponding author, with the exception of sensitivity data according to GDPR current regulations.

Results

Detection of SARS-CoV-2 measured by RT-qPCR in saliva and nasopharyngeal swab specimens and their association with COVID-19 duration
In total 44 patients participated in this study and patient characteristics are given in Table 1. In 40 patients where both NPH and saliva RT-PCR Ct values were available, we compared detection of SARS-CoV-2 in NPH and saliva swab specimens in each patient (Figure 1(a)). The Ct-value was significantly lower in NPH than saliva ($p < 0.01$). In patients where Ct-values for both types of specimens were available and above the threshold for detection (Ct < 40), the Ct-values in saliva correlated with those of NPH (n = 32, Pearson’s correlation coefficient $r = 0.64$, $p < 0.001$, Figure 1(b)). Ct-values of RT-PCR analysis in both NPH and saliva PCR correlated with COVID-19 duration ($r = 0.58$, $p < 0.001$; and $r = 0.53$, $p < 0.001$, respectively, Figure 1(c-d)). These findings suggest that saliva specimens could be a feasible alternative for SARS-CoV-2 detection, especially early in the disease course.
SARS-CoV-2 rapid antigen testing in saliva specimens with respect to PCR Ct values and COVID-19 duration

We then performed rapid antigen test using saliva specimens from the cohort participants. For saliva samples with RT-PCR Ct values lower than 25, Flowflex tests (ZetaGene-Hughes) were able to detect 64% (7 of 11) of positive cases, followed by PCL (55%, 6 of 11), Panbio (Abbott, 45%, 5 of 11) and Joinstar (45%, 5 of 11) (Table 2, Figure 2(a)). In the Ct-range between 25 and 29 of the saliva samples (n = 7), the positive detection was 57% by Flowflex, Panbio and Joinstar; and 43% by PCL (Table 2, Table 1. Baseline characteristics of the cohort participants.

| Characteristic                        | Value |
|--------------------------------------|-------|
| Total number                         | 44    |
| Age (years)                          |       |
| <60                                  | 19    |
| ≥60, <75                             | 13    |
| ≥75                                  | 12    |
| Sex N (%)                            |       |
| Male                                 | 22    |
| Female                               | 22    |
| COVID-19 duration (Days)             |       |
| Days ≤5                              | 7     |
| 5 < Days ≤10                         | 22    |
| Days >10                             | 15    |
| COVID-19 severity                   |       |
| Home quarantine                      | 2     |
| Hospitalized w/o oxygen therapy      | 19    |
| Hospitalized with oxygen therapy     | 19    |
| High flow nasal cannula              | 4     |
| Intensive care                       | 0     |

Figure 1. Detection of SARS-CoV-2 in saliva specimens and nasopharyngeal (NPH) swab specimens. Samples were obtained from 44 patients with COVID-19. (a) Detection of SARS-CoV-2 is presented by RT-PCR Ct values in patients with available NPH and saliva samples (n = 40). The lines indicate samples from the same patient. Ct values in NPH are significantly lower than those in saliva (p < 0.01 by Wilcoxon signed-ranked test). Pearson’s correlation coefficient was performed on RT-PCR Ct values above detection threshold (Ct<40) in (b) NPH and saliva samples Ct values (n = 32; \( r = 0.64, p < 0.001 \)); (c) NPH Ct values and symptom duration (n = 40; \( r = 0.58, p < 0.001 \)); (d) saliva Ct values and symptom duration (n = 34; \( r = 0.54, p < 0.001 \)).
In the Ct range higher than 29 (n = 16), the positive detection rate was further reduced to 19% (Flowflex), 9% (Abbott), 13% (Joinstar) and 13% (PCL) (Table 2, Figure 2(a)).

COVID-19 duration of 5 days or less (n = 7) corresponded to positive detection rate of 43% by Flowflex; and 29% by Panbio, Joinstar and PCL (Table 2 and Figure 2(b)). COVID-19 duration of more than 5 days but less than 10 days (n = 18) corresponded to higher positive detection rate: 56% by Flowflex; 44% by Panbio, Joinstar and PCL (Table 2 and Figure 2(b)). In patients with COVID-19 duration longer than 10 days (n = 9), Flowflex and PCL detected 11% of the positive cases, while Panbio and Joinstar detected none (Table 2 and Figure 2(b)).

Rapid antigen test offered the highest sensitivity when both saliva PCR values and disease duration were taken into consideration. In patients with saliva Ct values lower than 25 and disease duration shorter than 10 days (n = 9), 67% of the positive cases were detected by Flowflex, 44% by Panbio and Joinstar, and 56% by PCL (Table 2 and Figure 2(c)). Overall, Flowflex had the highest sensitivity in detecting viral antigen in saliva specimens from COVID-19 patients.

Discussion

We show that saliva specimens have similar levels of SARS-CoV-2 as compared to NPH swab specimens in patients admitted to hospital with COVID-19. RT-
qPCR Ct values of both saliva and NPH correlated with disease duration. We also show that rapid antigen test using saliva samples can detect SARS-CoV-2 in a subset of patients, mainly those with higher SARS-CoV-2 levels and shorter duration of symptoms.

Detection of SARS-CoV-2 by RT-PCR is still considered 'gold standard', while antigen tests for rapid diagnosis have gained an increasingly important role. Antigen tests detect viral proteins and suffer from a lower sensitivity than RT-PCR but are still very useful in certain clinical situations. For rule-in infection purposes, antigen tests have the advantage of being very fast. In the Swedish healthcare system, antigen tests are extensively used for screening of persons without symptoms of COVID-19 who have been exposed to infection or who have an increased risk of infection. However, a negative antigen test in a person with symptoms compatible with COVID-19 is not enough to exclude infection. It is worth to mention that this study does not address the issue of antigen test specificity, but rather with focus on sensitivity.

The relatively lower rate of positive case detection of rapid antigen tests in this study may be a consequence of several factors. Firstly, the cohort investigated in this study is not ideal to evaluate the usefulness of saliva antigen tests since the tests are intended to be used on persons without known COVID-19. Our results indicate, however, that saliva antigen tests are more likely to be positive early during the disease process and possibly the relatively low positive detection rate demonstrated in this study would be increased if subjects were recruited earlier during COVID-19. Similar studies using different patient cohorts to address these questions are ongoing. Second, with the exception of the antigen test from PCL, the tests used were validated for NPH sampling (Panbio and Joinstar) or nasal sampling (Flowflex). Therefore, the performance of the tests in this validation likely differs from the performance of the test when used according to

| Saliva-PCR | Flowflex (ZetaGene-Hughes) | Panbio (Abbott) | Joinstar | PCL |
|------------|-----------------------------|-----------------|----------|-----|
| Ct<25      | 64% (7/11)                  | 45% (5/11)      | 45% (5/11) | 55% (6/11) |
| Ct<29      | 57% (4/7)                   | 57% (4/7)       | 43% (3/7) | 11% (1/9) |
| Ct<40      | 19% (3/16)                  | 13% (2/16)      | 13% (2/16) | 16% (2/16)|
| COVID-19 duration |                 |                 |          |     |
| Days ≤5   | 43% (3/7)                   | 29% (2/7)       | 29% (2/7) | 11% (1/9) |
| Days ≤10  | 56% (10/18)                 | 44% (8/18)      | 44% (8/18)| 11% (1/9) |
| Days >10  | 11% (1/9)                   | 0% (0/9)        | 0% (0/9)  | 11% (1/9) |
| Saliva-PCR and COVID-19 duration |             |                 |          |     |
| Ct<25, Days<10 | 67% (6/9)                  | 44% (4/9)      | 44% (4/9) | 56% (5/9) |
the protocol. Thirdly, it has been shown that positive results of PCR may not necessarily reflect the presence of viable virus [12]. It is possible that PCR Ct values may not correspond to antigen test results, especially in longer disease duration where residues of viral genetic material from dead virus may be detected by PCR but not by antigen test. Finally, antigen test in this study was performed on saliva samples stored at −80°C and thawed to room temperature. It is recommended by the manufacturers that the testing is preferably performed on freshly collected samples, and therefore the freeze and thaw procedure may have an impact on testing sensitivity.

Currently, the antigen test is often performed on samples taken from NPH, and the sampling procedure requires handling by healthcare professionals. To increase the possibility to test a larger number of subjects, it would be a great advantage if antigen tests could be performed on saliva samples. This offers the possibility of self-testing, as well as much less discomfort in the sampling procedure. Based on our observation of lower, yet similar, detection of SARS-CoV-2 in saliva and NPH samples, we find saliva a promising candidate substrate for rapid SARS-CoV-2 antigen test. It is also worth mentioning that the performance of the rapid tests varies among products and that tests with higher positive detection rates should be preferred.

In conclusion, our study provides support for the potential application of saliva testing as an alternative diagnostic procedure to NPH swab COVID-19 testing. Collection of saliva samples can be easily performed by patients themselves, and therefore reduces direct interaction between patients and health care professionals. This allows for expansion of screening for SARS-CoV-2 in larger populations.

We thank ZetaGene Ltd. (Sweden) and Hughes Healthcare (UK) for donating the Flowflex SARS-CoV-2 rapid antigen tests. The Abbott-Panbio tests were supplied by the Skåne Region. The PCL tests were provided by LVL technologies GmbH Co. KG (Germany) and LAB Sweden (Sweden). We also thank Jointstar and Anil Vasishta for providing Jointstar COVID-19 rapid antigen tests.

**Disclosure statement**

YDM is the founder of and has an equity interest in ZetaGene Ltd. (Sweden), a company that is developing microfluidic technologies for point-of-care diagnostic solutions.

**Funding**

This work was supported by the Strategic Research Area Exodiab; Governmental funding of clinical research within the NHS; Swedish Foundation for Strategic Research; Swedish Research Council.

**Notes on contributors**

**Yang De Marinis** is Associate Professor at the Department of Clinical Sciences, Lund University, Sweden. She received her PhD on electrophysiology at Lund University and is currently a principal investigator with focus on chromatin immunoprecipitation sequencing, genome editing, clinical cohort studies and machine learning application. She is also a Visiting Professor in Medical Engineering at Shandong University, China; and holds a visiting chair at the Clinical Research Hospital, Chinese Academy of Sciences; the Division of Life Sciences of Medicine, University of Science and Technology of China. She is currently involved in several projects concerning COVID-19.

**Anne-Katrine Pesola** MD is consultant in Clinical Microbiology and Anesthesiology and Intensive Care. She is currently active in projects concerning COVID-19.

**Anna Söderlund Strand** (PhD) is an expert on PCR analysis and has much experience in clinical diagnostics and genotyping. Since the beginning of the pandemic, she has been working with several aspects of how to establish sensitive PCR-analysis of SARS-CoV-2 in a large-scale setting.

**Astrid Norman** is a medical student at Lund University, Sweden.

**Gustav Pernow** is an intern physician. He is currently doing postgraduate research concerning bacterial endocarditis and bacteria-platelet interactions.

**Markus Aldén** is an undergraduate student in biomedicine at Lund University. He is currently receiving training at Yang De Marinis’ lab for his thesis work related to COVID-19.

**Runtao Yang** is currently a lecturer at the School of Mechanical, Electrical and Information Engineering, Shandong University at Weihai, China. His research areas include machine learning, bioinformatics, and system biology.

**Magnus Rasmussen** is Professor of infection medicine and consultant in infectious diseases. He is an expert on bacterial endocarditis and is currently involved in several projects concerning COVID-19.

**Author contributions**

YDM, AKP, ASS, MR performed testing. AN, GP and MR collected saliva samples for the cohort. YDM, MA and RY performed data analysis. MR supervised the study. YDM wrote the manuscript with input from all co-authors.

**ORCID**

Yang De Marinis  
http://orcid.org/0000-0002-8081-2142

Magnus Rasmussen  
http://orcid.org/0000-0003-1588-5473

**References**

[1] Organization WH. WHO Coronavirus (COVID-19) Dashboard. Geneva: World Health Organization; 2021.

[2] Mahajan A, Manchikanti L. Value and validity of coronavirus antibody testing. Pain Physician. 2020;45(8;4S):S381–7.
La Marca A, Capuzzo M, Paglia T, et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reprod Biomed Online. 2020;41:483–499.

Bastos ML, Perlman-Arrow S, and Menzies D, et al. The sensitivity and costs of testing for SARS-CoV-2 Infection with saliva versus nasopharyngeal swabs: a systematic review and meta-analysis. Ann Intern Med. 2021;174(4):501–510. doi:10.7326/M20-6569.

Wang X, Tan L, Wang X, et al. Comparison of nasopharyngeal and oropharyngeal swabs for SARS-CoV-2 detection in 353 patients received tests with both specimens simultaneously. Int J Infect Dis. 2020;94:107–109.

Moisset X, Gautier N, Godet T, et al. Nasopharyngeal swab-induced pain for SARS-CoV-2 screening: a randomised controlled trial of conventional and self-swabbing. Eur J Pain. 2021;25(4):924–929.

Manabe YC, Reuland C, Yu T, et al. Self-collected oral fluid saliva is insensitive compared with nasopharyngeal swabs in the detection of severe acute respiratory syndrome coronavirus 2 in outpatients. Open Forum Infect Dis. 2021;8(2):ofaa648.

Williams E, Bond K, and Zhang B, et al. Saliva as a noninvasive specimen for detection of SARS-CoV-2. J Clin Microbiol. 2020;58(8):e00776–20 doi:10.1128/JCM.00776-20.

Sui Z, Zhang Y, Tu S, et al. Evaluation of saliva as an alternative diagnostic specimen source for SARS-CoV-2 detection by RT-dPCR. J Infect. 2021;82(1):e38–e40.

Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2. N Engl J Med. 2020;383(13):1283–1286.

Corman VM, Landt O, and Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020(3):25.

Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020;581(7809):465–469.